Francisco Kuri

Dr. Francisco Kuri Breña has over 30 years of experience working in the development of new synthetic and biologics drugs in the national and international pharmaceutical industry as well as in genetic medicine field. He has been part of companies like Probiomed, S.A. de C.V., Grupo Roche-Syntex de México and Landsteiner Scientific.
He has been recognized as a leader in the fields of biotechnology and development of new therapeutic drugs. Nowadays, he is member of the Biotechnology committee for regulation affairs at COFEPRIS, Mexico and coordinates the Committee for biotechnologic products in the Permanent Commission as part of Farmacopea de los Estados Unidos Mexicanos (equivalent to U.S. pharmacopeia). He is also part of the committee of translators for the U.S. Pharmacopeia.
As part of Landsteiner Scientific he is in charge of licensing and pharmaceutical development of biotechnologic and genomic products that sustain the growth of the company.